Upstream Bio, Inc. cotiza a 4.17 USD y tiene una capitalización bursátil de $228M. En los últimos 12 meses ha facturado $3M con un margen de flujo de caja libre del -4675.5%. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud
Upstream Bio, Inc., a clinical-stage biotechnology company, develops treatments for inflammatory diseases focusing on severe respiratory disorders. It offers verekitug, which is in Phase 2 trials for the treatment of severe asthma and chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease an…
| Periodo | 2026-11 | 2026-08 | 2026-05 | 2026-03 |
|---|---|---|---|---|
| Real | — | — | $-0.75 | $-0.78 |
| Estimado | $-0.73 | $-0.76 | $-0.75 | $-0.70 |
| Sorpresa | — | — | +0.0% | -11.4% |
| Métrica | UPB | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | — | 57.0% | — |
| Operating Margin | -5618.8% | -38.6% | -5580.2% |
| Net Margin | -5026.0% | -33.6% | -4992.5% |
| FCF Margin | -4675.5% | -13.9% | -4661.7% |
| ROE | -42.2% | -40.4% | -1.8% |
| ROA | -40.5% | -32.0% | -8.5% |
| Current Ratio | 26.15 | 2.84 | +23.31 |
| Debt / Equity | — | 0.28 | — |